Skip to main content
Premium Trial:

Request an Annual Quote

Ymir Genomics, OHSU Knight Cancer Institute Collaborate to Develop HCC Biomarkers

NEW YORK (GenomeWeb) – Massachusetts-based Ymir Genomics today announced a strategic collaboration with the Knight Cancer Institute at Oregon Health and Science University (OHSU) to develop urinary biomarkers that will help detect hepatocellular carcinoma in at-risk patient populations.

As part of the collaboration, Ymir will isolate extracellular vesicles and examine the miRNA profiles of urine samples from liver cancer patients and high-risk cirrhotic patient controls. OHSU will then take the vesicle preps and determine specific protein profiles.

The collaboration will use Ymir's urinary extracellular vesicle technology and the Knight Cancer Institute OHSU Proteomics Shared Resource, which was built to make spectrometry-based protein analysis capabilities available to the OHSU biomedical research community.

"With our technology and OHSU's considerable expertise, I am confident that we can find these much-needed biomarkers," Ymir Genomics CSO Shannon Pendergrast said in a statement. "Imagine at-risk patients monitoring their liver health by simply dropping a urine sample into the mail. The stability of exosomes in urine makes this possible."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.